AMCS unveils the AMCS Platform Summer ‘23 edition, the second release this year, delivering exciting new productivity features and a dynamic customer experience for environmental, transportation, waste, recycling and resource operators
10.7.2023 18:15:00 EEST | Business Wire | Press release
AMCS, the world leading technology provider for the environmental, waste, recycling and environmental health and safety industries, today announced the global launch of the AMCS Platform 2023 Summer release. The release offers important new benefits and features, including:
- Order-to-Cash Automation to simplify and accelerate cashflow – Newly streamlined and optimised processes enable operators to invoice faster and more easily, so they can get paid sooner, creating a better experience for both users and customers. A new cash collection management module provides automated credit control to collect all receivables.
-
Maximised Asset Utilisation – The new Equipment Inventory module optimises visibility and control over container assets by quickly identifying slow-moving containers, ensuring they’re available to meet market demand, and allowing operators to optimise sales and minimise the costs associated with the physical loss of containers.
Significant enhancements to the Transport Solutions platform user experience will boost scheduling and maintenance productivity of both fleet owners and planners, empowering them to optimise utilisation of company fleet assets.
- Digitalisation of Purchase to Pay – A streamlined process will allow recyclers to seamlessly manage tickets for the purchase of feedstock. Scrap recyclers can capture supplier data quickly and easily to ensure regulatory compliance. Integrated, flexible supplier payments allow cash (including ATM), check, and ACH, as well as exciting emerging digital instant payment types (using AMCS Pay) including push-to-debit and pre-paid cards. These connected, digitalised processes will automate, connect, and accelerate purchasing, compliance, scale, supplier payment, and financial tasks, boosting both efficiency and competitiveness.
“Our continued investment in automation processes is the major theme of the AMCS Platform. The Summer ’23 release delivers real business value,” says Elaine Treacy, Global Product Director at AMCS. Treacy continues, “Newly optimised ‘order to cash’ processes will drive faster payments with less effort, reducing the risk of overdue payments and bad debt. Our new streamlined ‘purchase to pay‘enables recyclers to purchase feedstock in an efficient and regulatory compliant manner. In addition to supplier settlements using cash and checks, we are introducing exciting digital payment options.”
The investment in enhanced user experiences and a new equipment inventory feature will allow AMCS customers to drive greater utilisation and financial return from their container and truck assets, and thus improve their sales. Other highlights of the summer release include:
- Full integration of AMCS Vision AI into the AMCS Platform, providing new dashboards for insight as well as options to automatically charge for exceptions such as overfills and contamination.
- A new Sustainability Dashboard on the AMCS Customer Portal, allowing customers to share key sustainability performance metrics with their end users.
- New Customer Self-Serve features, including support for Interactive Voice Response (IVR) for PCI compliant payments and the digital exchange of Duty of Care (UK) compliance documentation.
- For municipal operators, more streamlined invoice processing of direct residential subscribers and enhanced controls on the service status of customers, depending on their payment standing.
- A new and improved AMCS Academy online customer training platform, with more compelling and engaging training experiences.
To learn more about AMCS Platform Summer ‘23 Release, visit www.amcsgroup.com
About AMCS Group
AMCS, with offices in Europe, North America and Australia is a global technology leader for the environmental, waste, recycling, and resource industries. We help over 4,000 customers reduce their operating costs, increase asset utilisation, optimise margins, drive sustainability, and improve customer service. Our enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world. Read more about AMCS at www.amcsgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230628408946/en/
Contact information
Austen Lees
Sirius Communications
austen@siriuscomms.co.uk
Tel.: 00447773813210
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
